Oxford-based Sitryx, which also has operations in Boston in the US, was founded in 2018 with seed funding from SV Health ...

Eli Lilly's oral GLP-1 agonist orforglipron was more effective than Novo Nordisk's recently launched Wegovy pill in a head-to ...

A recent study found that up to 40% of trials might be untrustworthy due to flaws in design, improper data collection, and ...

Asahi Kasei has agreed a €780 million (around $920 million) price tag for Wuppertal-based Aicuris, which is hoping for FDA ...

Eisai has a position in kidney cancer with Lenvima (lenvatinib), a kinase inhibitor that is approved for use in combination with MSD's cancer immunotherapy Keytruda (pembrolizumab) as a first-line ...

The manufacturing of GLP-1s involves a complex process that includes peptide synthesis, amino acid coupling, cleavage, purification, and chemical modifications. The solid-phase peptide synthesis (SPPS ...

Who controls the narrative, where the money is going, and why patients need to be at the centre of what comes next News headlines, on your Instagram feed, song lyrics, in day-to-day conversation; few ...

Sarepta's Doug Ingram and Alkermes' Richard Pops have both announced their retirement and will step down later this year. Two long-serving pharma chief executives have announced their departures, as ...

As Rare Disease Day approaches, in a special episode of the pharmaphorum podcast, sponsored by AOP Health, we spoke with Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, at AOP ...

Retention has always been a central concern in long-term studies, but obesity trials present a particular challenge. For those assigned to receive the drug candidate in question, the effects are ...

35Pharma's lead development programme is HS235, an activin receptor-targeting fusion protein that has completed phase 1 ...

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 ...